Automated sample-preparation and mass spectrometry-based assays for free and total Infliximab: Enabling therapeutic drug monitoring of monoclonal antibodies
The dual-assay enables routine quantification of biologic-ADA interactions in a cost effective, high throughput LC-MS/MS workflow. It addresses key limitations of immunoassays and may improve detection of immunogenicity in patients receiving biologic therapy. The method is generalizable to other therapeutic antibodies affected by ADA interference.
Authors
- Catherine Toong (ORCID: https://orcid.org/0000-0002-7034-7187)
- David G. Harman (ORCID: https://orcid.org/0000-0003-4376-832X)
- Melissa Sam (ORCID: https://orcid.org/0000-0003-1854-1289)
- William A. Donald
Institutions
- Liverpool Hospital (AU)
- UNSW Sydney (AU)
- Ingham Institute (AU)
- Western Sydney University (AU)
Publication Details
- Journal
- Analytica Chimica Acta
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1016/j.aca.2026.345222
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00